ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0916

Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0721

Validation of New Antirheumatic Drug Use as a Proxy for Increased JIA Disease Activity

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0716

Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0790

Vitamin D Polygenetic Risk Score and the Association with RA Autoantibodies Among First-Degree Relatives of RA Subjects

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0633

Vitamin D Serum Status in a Cohort of COVID-19 Patients

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0862

Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0655

Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0850

What Does It Mean to Be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0726

Who Ordered the Stiff One? Characteristics of Polyarticular Juvenile Idiopathic Arthritis Patients Associated with the Presence and Increased Duration of Joint Stiffness

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0760

X-rays Bone Erosions Are Uncommon in Anti-CCP Positive Individuals At-risk of Rheumatoid Arthritis with Musculoskeletal Symptoms Without Clinical Synovitis, and Do Not Predict the Development of Inflammatory Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

10:00AM-10:50AM: Abstract Number: 0959

Altered Gut Microbiome in Dermatomyositis

Muscle Biology, Myositis & Myopathies (0955–0959)

10:00AM-10:50AM: Abstract Number: 0956

An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions

Muscle Biology, Myositis & Myopathies (0955–0959)

10:00AM-10:50AM: Abstract Number: 0963

Chronic Obstructive Pulmonary Disease Associated with Prolonged Opiate Use, Increased Short-Term Complications and the Need for Revision Surgery Following Total Knee Arthroplasty

Orthopedics, Low Back Pain, & Rehabilitation (0960–0964)

10:00AM-10:50AM: Abstract Number: 0961

Development of a Pain Sensitivity Index to Examine the Transition from Intermittent to Constant Pain in Knee Osteoarthritis: The Multicenter Osteoarthritis Study

Orthopedics, Low Back Pain, & Rehabilitation (0960–0964)

10:00AM-10:50AM: Abstract Number: 0955

Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)

Muscle Biology, Myositis & Myopathies (0955–0959)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].